Please assess the completion status of the following clinical trial:

Trial Title: Safety and Effectiveness Study of a Candidate Vaginal Microbicide for Prevention of HIV

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age 18-40 years (inclusive)~* Able and willing to provide written informed consent to be screened for, and to enrol in, the study.~* Able and willing to provide adequate locator information for study retention purposes.~* Sexually active, defined as having had vaginal intercourse at least twice in the past 30 days prior to screening.~* HIV negative on testing performed by study staff within 30 days of enrolment.~* Have a negative pregnancy test which was performed by study staff within 21 days of enrolment~* Agree to use a non-barrier form of contraceptive~* Agree to adhere to study visits and procedures~Exclusion Criteria:~* History of adverse reaction to latex.~* Plans any of the following during the next 16 to 30 months (depending the anticipated date of study completion):~  * To travel away from the study site for more than 30 consecutive days.~ * To relocate away from the study site.~ * To become pregnant~ * To enrol in any other study of an investigational product or behaviour modification related to HIV prevention.~* Has a creatinine clearance \<50ml/min, as estimated using the method of Cockcroft and Gault(33).~* Has active Hepatitis B infection (since January 2009)~* Has a clinically apparent pelvic examination finding (observed by study staff) involving deep epithelial disruption. Otherwise eligible participants with pelvic examination findings involving deep epithelial disruption may proceed with enrolment after the findings have resolved and the inclusion/exclusion are met.~* Has in the past year participated in any research related to any vaginally applied product/s.~* Has current STI symptoms and/or other reproductive tract infection requiring treatment, as assessed by study staff. Otherwise eligible participants diagnosed during screening with infection(s) requiring treatment may be enrolled provided that treatment has commenced.~* Has any other condition that, based on the opinion of the Investigator or designee, would preclude provision of informed consent, make participation in the study unsafe, complicate interpretation of study outcome data, or otherwise interfere with achieving the study objectives.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 40 Years
- Healthy Volunteers: t

Study Arms:
- 1 (Type: EXPERIMENTAL): Tenofovir gel (a reverse transcriptase inhibitor)
- 2 (Type: PLACEBO_COMPARATOR): Universal HEC placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).